Last reviewed · How we verify

NCT05018247: PETREVASC

Early Revascularization in Stable Ischemic Heart Disease Using P.E.T. Imaging

Terminated NA Last updated 18 October 2023
What this trial tests

NA trial testing Revascularization by Coronary Artery Bypass Graft or Percutaneous Coronary Intervention in Ischemic Heart Disease in 14 participants. Terminated before completion.

Timeline
4 May 2021
Primary endpoint
19 May 2022
19 May 2022

Quick facts

Lead sponsorThe University of Texas Health Science Center, Houston
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment14
Start date4 May 2021
Primary completion19 May 2022
Estimated completion19 May 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

The University of Texas Health Science Center, Houston

Who can join

18 and older, any sex, with Ischemic Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the impact of revascularization and Optimal Medical Treatment (OMT) on the extent of severely reduced coronary flow capacity in stable ischemic heart disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ischemic Heart Disease

Currently open trials in the same condition.

Other The University of Texas Health Science Center, Houston trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05018247.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing